{
    "root": "edda84e4-e450-466a-b629-b0bc3a6b972d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "regadenoson",
    "value": "20240925",
    "ingredients": [
        {
            "name": "REGADENOSON",
            "code": "2XLN4Y044H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135613"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, DIHYDRATE",
            "code": "94255I6E2T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13404"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "regadenoson injection pharmacologic stress agent indicated radionuclide myocardial perfusion imaging ( mpi ) patients unable undergo adequate exercise stress .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended dose regadenoson injection 5 ml ( 0.4 mg regadenoson ) administered intravenous injection within 10 seconds . \u2022patients instructed avoid consumption products containing methylxanthines , including caffeinated coffee , tea caffeinated beverages , caffeine-containing products , aminophylline theophylline least 12 hours scheduled radionuclide mpi [ ( 7.1 ) pharmacology ( 12.2 ) ] . \u2022parenteral products inspected visually particulate matter discoloration prior , whenever solution container permit . administer regadenoson injection contains particulate matter discolored . \u2022administer regadenoson intravenous injection within 10 seconds peripheral vein using 22 gauge larger catheter needle . \u2022administer 5 ml saline flush immediately injection regadenoson . \u2022administer radionuclide myocardial perfusion imaging agent 10\u201320 seconds saline flush . radionuclide may injected directly catheter regadenoson injection .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "regadenoson injection supplied sterile , preservative-free solution containing 0.08 mg/ml regadenoson following package : unit sale concentration ndc 36000-364-01 ( single-dose 5 ml pre-filled plastic schott toppac syringe luer lock fitting ) 0.4 mg/5 ml ( 0.08 mg/ml ) store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0to 86\u00b0f ) [ usp controlled room temperature ] . discard unused portion .",
    "adverseReactions": "administer regadenoson injection patients : \u2022second- third-degree av block , \u2022sinus node dysfunction unless patients functioning artificial pacemaker [ ( 5.2 ) ] .",
    "indications_original": "Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.",
    "contraindications_original": "The recommended dose of regadenoson injection is 5 mL (0.4 mg regadenoson) administered as an intravenous injection within 10 seconds.\n                  \n                     \n                        \u2022Patients should be instructed to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine-containing drug products, aminophylline and theophylline for at least 12 hours before a scheduled radionuclide MPI [see Drug Interactions (7.1) and Clinical Pharmacology (12.2)\n                        ].\n                     \n                        \u2022Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer regadenoson injection if it contains particulate matter or is discolored.\n                     \n                        \u2022Administer regadenoson as an intravenous injection within 10 seconds into a peripheral vein using a 22 gauge or larger catheter or needle.\n                     \n                        \u2022Administer a 5 mL saline flush immediately after the injection of regadenoson.\n                     \n                        \u2022Administer the radionuclide myocardial perfusion imaging agent 10\u201320 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as regadenoson injection.",
    "warningsAndPrecautions_original": "Regadenoson injection is supplied as a sterile, preservative-free solution containing 0.08 mg/mL regadenoson in the following package:\n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Unit of  Sale\n                              \n                           \n                           \n                              \n                                 Concentration\n                              \n                           \n                        \n                        \n                           \n                              NDC 36000-364-01\n                              (Single-dose 5 mL pre-filled plastic SCHOTT TOPPAC syringe with luer lock fitting)\n                           \n                           \n                              0.4 mg/5 mL\n                              (0.08 mg/mL)\n                           \n                        \n                     \n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Discard unused portion.",
    "adverseReactions_original": "Do not administer regadenoson injection to patients with:\n                  \n                     \n                        \u2022Second- or third-degree AV block, or\n                     \n                        \u2022sinus node dysfunction\n                  \n                  unless these patients have a functioning artificial pacemaker [see Warnings and Precautions (5.2)\n                     ].",
    "drug": [
        {
            "name": "regadenoson",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135613"
        }
    ]
}